摘要
目的 :观察健择为主联合化疗方案治疗晚期非小细胞肺癌的临床疗效及毒副反应。方法 :42例晚期非小细胞肺癌 ,2 6例采用健择 10 0 0mg/m2 ,d1、d8;DDP 3 0mg/m2 ,d1～d3 。 16例采用健择 10 0 0mg/m2 ,d1、d8;紫杉醇 60mg/m2 ,d1、d8。两方案均 3个周重复 ,3个周期以上评价疗效。结果 :42例中CR 1例 ,PR 2 0例 ,SD 14例 ,PD 7例 ,有效(CR +PR)率 5 0 % (2 1/4 2 ) ,初治有效率5 4 2 % (13 /2 4) ,复治有效率 44 4% (8/18)。健择 +DDP组 (其中 2 4例为初治 ) ,CR 1例 ,PR 12例 ,有效率 5 0 %(13 /2 6)。健择 +紫杉醇组有效率 5 0 %(8/16)。毒副反应主要为骨髓抑制和消化道反应 ,12 6个周期中Ⅲ～Ⅳ度粒细胞下降 19例次 (15 0 % ) ,Ⅲ～Ⅳ度血小板下降 3 2例次 (2 5 4% ) ,Ⅲ～Ⅳ度消化道反应 45例次 (3 5 7% ) ;Ⅱ～Ⅲ度肝功能损害 5 0例次 (3 9 6% )。结论 :健择为主联合化疗方案治疗晚期非小细胞肺癌有较好疗效 ,毒副反应可耐受 ,特别是健择 +紫杉醇治疗复治非小细胞肺癌有较高疗效 ,值得临床进一步研究观察。
OBJECTIVE:To investigate therapeutic effects and side effects of advanced NSCLC treated by combining chemotherapy base on gemcitabine.METHODS:Forty two cases of advanced NSCLC were divided into two groups:Group 1,26 cases treated by gemcitabine 1 000 mg/m 2 at d 1,d 8 and 30 mg/m 2,DDP at d 1 d 3;Group 2,16 cases treated by gemcitabine 1 000 mg/m 2 and paclitaxel 60 mg/m 2 at d 1,d 8.Both groups were recycled every 3 weeks and the therapeutic effects were evaluated after 3 cycles.RESULTS:CR was 1 cases,PR 20 cases,SD 14 cases,PD 7 cases and CR+PR were 21 cases (response rate 50 0%) in 42 cases observed.In 24 cases of primary treatments:CR+PR were 13 cases (response rate 54 2%);in 18 cases re treatments:CR+PR 8 cases (response rate 44 4%);in 16 cases of advanced NSCLC re treated by gemcitabine combined with paclitaxel:CR+PR 8 cases (response rate 50%).For side effects,in total 126 cycles chemotherapy,most cases showed bone marrow suppression and symptoms of gastrointestinal side effects,which included 19 cases of Ⅲ-Ⅳ grades leukocytopenia (15%),32 cases of Ⅲ-Ⅳ grades soterocytopenia (25 4%),45 cases of Ⅲ-Ⅳ grades symptoms of gastrointestinal side effects (35 7%),50 cases of Ⅱ-Ⅲ grades abnormal liver function (36 9%).CONCLUSIONS:Good therapeutic effects have been achieved in the treatment of advanced NSCLC by combining protocol based on gemcitabine,and the side effects are tolerable,and nice therapeutic effects obtained in the re treatment of NSCLC by gemcitabine combined with paclitaxel.It is valuable to investigate its therapeutic effects more deeply.
出处
《肿瘤防治杂志》
2004年第2期162-163,167,共3页
China Journal of Cancer Prevention and Treatment
